The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–Genetesis, Inc. announced today that its flagship product, CardioFlux®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute […]
– Strategic investments round out $9.2M Series B round of financing – Sajid Malhotra joins Genetesis Board of Directors MASON, Ohio, May 7, 2020 /PRNewswire/ — Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFlux™ imaging, today announced several important […]
SAN JOSE, Calif.–(BUSINESS WIRE)–TDK Corporation (TSE:6762) announces that subsidiary TDK Ventures Inc. adds to its growing portfolio of companies with an investment in Genetesis, a world leader in non-invasive biomagnetic imaging. Genetesis is the fifth investment by the TDK corporate venture capital (CVC) […]
Initial study shows Genetesis, Inc.’s CardioFlux Magnetocardiograph (MCG) has potential to rule patients out for Coronary Artery Disease. MASON, Ohio, Jan. 30, 2020 /PRNewswire/ — Undiagnosed chest pain sends 8-10 million Americans to Emergency Departments annually, making it the second most common complaint. […]
MASON, Ohio–(BUSINESS WIRE)–Genetesis, a medical technology company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, has received FDA 510(k) clearance for its cardiac imaging platform. The platform pairs the CardioFlux™ Magnetocardiograph with the integrated […]
